Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

GLP Toxicology and Biodistribution of Intrathecally Administered Antisense Oligonucleotides (ASOs)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

GLP Toxicology and Biodistribution of Intrathecally Administered Antisense Oligonucleotides (ASOs)

GLP Toxicology and Biodistribution for Intrathecal ASOs

CELL & GENE | RNA | BIOLOGICS

Intrathecal administration of antisense oligonucleotides (ASOs) offers direct access to the central nervous system (CNS), yet a significant portion of the therapeutic can distribute systemically. A robust, GxP-compliant toxicology and biodistribution program is necessary to quantify this exposure and characterize the complete safety profile. These studies provide the data package required to de-risk clinical development and support successful Investigational New Drug (IND) applications.

    What is the primary challenge in ASO biodistribution following intrathecal administration?

    A: The primary challenge is unintended systemic leakage from the cerebrospinal fluid (CSF) into peripheral circulation. This can lead to ASO accumulation in non-target tissues, such as the liver and kidneys, creating a potential for off-target toxicity that must be thoroughly evaluated.

    How does GxP compliance impact intrathecal toxicology studies?

    A: GxP compliance ensures the integrity, reliability, and regulatory acceptance of nonclinical safety data. For intrathecal ASO studies, this framework governs every phase from dose formulation and administration to bioanalysis, clinical observations, and final histology assessments for an IND submission.

    What are the key endpoints in a GxP ASO toxicology study?

    A: Key endpoints include detailed clinical observations, neurobehavioral assessments, CSF and serum analysis, and terminal collection of tissues. A comprehensive histology evaluation of the CNS and key peripheral organs is performed, alongside bioanalytical quantification of the ASO to correlate tissue exposure with findings.

    Why is non-target tissue biodistribution a focus for intrathecal ASOs?

    A: While the therapeutic target is in the CNS, systemic exposure can impact the overall safety profile. Quantifying ASO levels in peripheral organs provides the data needed to understand potential liabilities and establish a therapeutic window, directly informing clinical trial design and safety monitoring plans.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Defining the Safety Profile of CNS-Targeted Oligonucleotides

Intrathecal delivery is a validated strategy for targeting neurological disorders with ASOs. However, the anatomical barriers between the CSF and systemic circulation are permeable. This creates a technical challenge where a portion of the administered dose invariably enters the bloodstream, leading to widespread peripheral tissue exposure.

Understanding the fate of the entire dose is a core objective of any IND-enabling program. Scientific literature reinforces this principle across modalities; studies examining CSF-administered vectors have demonstrated that 60-90% of the total dose can be measured systemically (PMID: 37624734). This highlights the necessity of designing toxicology studies that account for both CNS and non-target organ system effects. A program’s success depends on accurately characterizing this distribution to build a comprehensive safety profile.

Integrated GxP Framework for ASO Toxicology

A successful IND submission for an intrathecal ASO requires a well-designed, GxP-compliant nonclinical program. At our >100,000 sq ft facility, we execute these studies within a framework designed for regulatory acceptance, supporting an average 18-24 month IND timeline for our partners.

Our GxP toxicology programs for ASOs incorporate several integrated components:

  • Dose Range-Finding (DRF) Studies: Initial non-GxP studies to identify a well-tolerated dose range for the definitive GxP study.

  • GxP-Compliant Safety Assessment: In vivo studies conducted under rigorous GxP standards to evaluate for any potential toxicities.

  • Quantitative Bioanalysis: Using methods such as qPCR or LC-MS to determine ASO concentrations in the CNS, CSF, and a full panel of peripheral tissues.

  • Comprehensive Histology: Board-certified pathologists conduct microscopic examination of the brain, spinal cord, and peripheral organs to identify any test article-related findings.

Since 2019, our scientific teams have maintained a 100% success rate for IND-enabling studies, a track record we continue under the Franklin Biolabs brand, which launched in 2024.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

Animal Welfare and Advanced Methodologies

.

Our animal care and use program is registered with the USDA, and through our strategic partnership with the Bioculture Group, we operate under AAALAC International accreditation. We strictly follow the principles of the 3Rs (Reduction, Refinement, and Replacement) to ensure the ethical and humane treatment of all animals in our care. Through strategic partnerships, we integrate advanced techniques that enhance data quality while minimizing animal use.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities